CompanyGraph
At a glance
- Depends onDownstream position: depends on 10 industries, supplies 5
- ScaleMarket cap is $3.24B, above the global median of $1.15B
- FinancialsAltman Z-Score 2.81: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.24BUSDvs all stocks (USD)
Revenue (TTM)
652.56MUSDvs all stocks (USD)
Profit Margin
-15.79%Beta
0.3430xvs all stocks
52-Week Change
189.79%vs all stocks
Market Capitalization
3.24BUSDvs all stocks (USD)
Enterprise Value
3.31BUSDvs all stocks (USD)
Forward P/E
52.52xPrice to Sales (TTM)
4.97xPrice to Book (MRQ)
3.32xEnterprise to Revenue
5.07xEnterprise to EBITDA
-59.91xGross Margin
62.52%Profit Margin
-15.79%Operating Margin
-13.81%Return on Assets (TTM)
-4.40%Return on Equity (TTM)
-10.66%Revenue (TTM)
652.56MUSDvs all stocks (USD)
Revenue per Share (TTM)
4.37USDUpdated Jul 18, 2026Quarterly Revenue Growth
19.80%Gross Profit (TTM)
387.59MUSDvs all stocks (USD)
EBITDA (TTM)
-55.25MUSDvs all stocks (USD)
Net Income (TTM)
-103.05MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
19.76%Operating Cash Flow (TTM)
106.02MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
116.78MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%Revenue
624.02MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
267.81MUSDFY2025 · Dec 31, 2025Gross Profit
356.20MUSDFY2025 · Dec 31, 2025Operating Income
-118.58MUSDvs all stocks (USD)
Pre-tax Income
-119.19MUSDFY2025 · Dec 31, 2025Income Tax Expense
2.49MUSDFY2025 · Dec 31, 2025Net Income
-121.68MUSDFY2025 · Dec 31, 2025EBIT
-106.49MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-29.16MUSDFY2025 · Dec 31, 2025Research & Development
162.66MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
312.13MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
12.29MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
12.70MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.8300USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.8300USDFY2025 · Dec 31, 2025Basic Shares Outstanding
146.90MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
146.90MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-121.68MUSDFY2025 · Dec 31, 2025Operating Cash Flow
94.17MUSDFY2025 · Dec 31, 2025Free Cash Flow
65.52MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
180.56MUSDFY2025 · Dec 31, 2025Income Tax Paid
1.34MUSDFY2025 · Dec 31, 2025Interest Paid
11.59MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-121.68MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
77.85MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
1.43MUSDFY2025 · Dec 31, 2025Stock-based Compensation
117.32MUSDFY2025 · Dec 31, 2025Other Non-cash Items
43.27MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-6.22MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
4.49MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-22.29MUSDFY2025 · Dec 31, 2025Capital Expenditures
-28.65MUSDFY2025 · Dec 31, 2025Purchase of Investments
-389.84MUSDFY2025 · Dec 31, 2025Sale of Investments
223.11MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-195.38MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
180.00MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-2.33MUSDFY2025 · Dec 31, 2025Other Financing Charges
-172.96MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
4.71MUSDFY2025 · Dec 31, 2025Shares Outstanding
156.37MSharesUpdated Jul 18, 2026Float Shares
146.59MSharesUpdated Jul 18, 2026Shares Short
25.35MSharesUpdated Jul 18, 2026Short Ratio
3.65daysvs all stocks
Short % of Shares Outstanding
18.89%vs all stocks
% Held by Insiders
4.38%vs all stocks
% Held by Institutions
91.42%vs all stocks
Total Cash (MRQ)
330.49MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.11USDUpdated Jul 18, 2026Total Debt (MRQ)
397.75MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.4071xCurrent Ratio (MRQ)
3.00xBook Value per Share (MRQ)
6.25USDUpdated Jul 18, 2026Total Assets
1.50BUSDvs all stocks (USD)
Total Current Assets
506.71MUSDFY2025 · Dec 31, 2025Total Liabilities
569.90MUSDFY2025 · Dec 31, 2025Total Non-current Assets
992.77MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
375.90MUSDFY2025 · Dec 31, 2025Total Current Liabilities
194.00MUSDFY2025 · Dec 31, 2025Cash
87.74MUSDFY2025 · Dec 31, 2025Cash Equivalents
92.82MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
180.56MUSDFY2025 · Dec 31, 2025Other Short-term Investments
181.20MUSDFY2025 · Dec 31, 2025Accounts Receivable
118.03MUSDFY2025 · Dec 31, 2025Accounts Payable
17.61MUSDFY2025 · Dec 31, 2025Short-term Debt
62.98MUSDFY2025 · Dec 31, 2025Deferred Revenue
41.35MUSDFY2025 · Dec 31, 2025Other Current Liabilities
971.00KUSDFY2025 · Dec 31, 2025Long-term Debt
367.20MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
8.70MUSDFY2025 · Dec 31, 2025Common Stock (Book)
3.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.11BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
929.58MUSDvs all stocks (USD)
52-Week Low
6.29USDUpdated Jul 18, 202652-Week High
34.82USDUpdated Jul 18, 202652-Week Change
189.79%vs all stocks
Beta
0.3430xvs all stocks
50-Day MA
18.68USDUpdated Jul 18, 2026200-Day MA
16.12USDUpdated Jul 18, 2026Avg 10-Day Volume
5.38MSharesUpdated Jul 18, 2026Avg 30-Day Volume
5.59MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-0.6900USDUpdated Jul 18, 2026Other Income / Expense
-195.00KUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.63Profit Margin: -0.16
Financial Health
Altman Z-Score 2.81: safe zoneNotable
Altman Z-Score: 2.81
Supply Chain
Downstream position: depends on 10 industries, supplies 5Notable
Outgoing: 5.00Incoming: 10.00
High connectivity hub: 15 industry connectionsNotable
Total Connections: 15.00
Scale
Market cap is $3.24B, above the global median of $1.15BNotable
Market cap (USD): 3,242,680,000Global Median: 1,146,734,693.424
Revenue is $652.56M, above the global median of $520.53MNotable
Revenue (USD): 652,564,992Global Median: 520,528,949.311
Levered free cash flow is $116.78M, above the global median of $16.24MNotable
Levered free cash flow (USD): 116,781,872Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Megaport Limited
Tier 1FlowRecurring-Revenue Lock-InInterfaceProduction
Privia Health Group, Inc.
Tier 1FlowRecurring-Revenue Lock-InInterfaceProduction
RingCentral Inc.
Tier 1FlowRecurring-Revenue Lock-InInterfaceProduction
NCR Atleos Corporation
Tier 1FlowRecurring-Revenue Lock-InInterfaceProduction
Diebold Nixdorf Inc.
Tier 1FlowRecurring-Revenue Lock-InProductionInterface
Paymentus Holdings Inc.
Tier 1FlowRecurring-Revenue Lock-InInterfaceProduction
Newland Digital Technology Co., Ltd.
Tier 1FlowRecurring-Revenue Lock-InProductionRisk
Box Inc.
Tier 1FlowRecurring-Revenue Lock-InInterfaceProduction
Waystar Holding Corp.
Tier 1FlowRecurring-Revenue Lock-InProductionInterface
Bill Holdings Inc.
Tier 1FlowRecurring-Revenue Lock-InInterfaceProduction
Companies that share active interpretations — structural patterns currently present in both stocks.
Immunome Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Hyliion Holdings Corp.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Kopin Corporation
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC